FDA Brief

Warning letters Drugs

FDA warning letter to

Swift Digital Group LLC dba Swadesii

High riskIssued Nov 17, 2025Posted Nov 25, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Swadesii that its website sells unapproved drugs with claims to treat serious conditions including measles, cancer and Alzheimer's.

What happened

FDA reviewed https://swadesii.com/ in September 2025 and found the website offered Swadesii products for sale in the United States. FDA said the product labeling included claims to cure, mitigate, treat, or prevent serious and/or life-threatening conditions such as measles, cancer, diabetes, stroke, Alzheimer's, and hepatitis. FDA also said the ophthalmic product Elaneer Kuzhambu is especially concerning because eye administration bypasses some of the body's natural defenses.

What FDA found

  1. The website offers unapproved new drugs for sale in the United States without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  2. The product labeling includes claims to cure, mitigate, treat, or prevent diseases, which makes the products drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
  3. The products are not generally recognized as safe and effective for their labeled uses and are therefore new drugs.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  4. The homeopathic products are still subject to drug approval, adulteration, and misbranding requirements.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. Elaneer Kuzhambu is an unapproved ophthalmic drug product, which is especially concerning because eye products bypass some natural defenses.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

Notify FDA in writing within 15 working days of the specific steps taken to correct the violations, explain steps to prevent recurrence, and include related documentation. If the company believes the products are not violations, it must include its reasoning and supporting information.

Who should pay attention

  • online sellers of Ayurvedic and homeopathic products
  • brands and importers that make disease-treatment claims
  • consumers using such products for serious conditions

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk